The global Adalimumab market is projected to grow from US$ 148 million in 2024 to US$ 192.7 million by 2030, at a Compound Annual Growth Rate (CAGR) of 4.5% during the forecast period.

Adalimumab Market

Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis.

Adalimumab is a widely used biologic medication that belongs to the class of tumor necrosis factor (TNF) inhibitors. It is primarily prescribed for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Autoimmune diseases are on the rise globally, affecting millions of people. Adalimumab is one of the leading treatment options for these conditions, driving the demand for the medication. Improved awareness and diagnosis of autoimmune diseases have led to an increased demand for effective treatment options like adalimumab. Biologic drugs, including adalimumab, have gained popularity due to their targeted treatment approach and potential for better disease management. Patients are increasingly opting for these medications over conventional therapies, driving the market growth of adalimumab. Adalimumab has received approvals for an expanding range of indications, including pediatric use and additional inflammatory conditions. The availability of more indications and treatment options has expanded the addressable market for adalimumab. The expiration of adalimumab's patent in various regions has opened the doors for the entry of biosimilar versions of the drug. Biosimilars offer competitive pricing, increasing market accessibility and potentially driving the overall market growth. Reimbursement policies and insurance coverage play a significant role in the adoption and market drive of adalimumab. Favorable policies and coverage encourage patient access and contribute to the growth of the market. Advances in drug delivery systems, such as autoinjectors and pre-filled syringes, have increased the convenience and ease of administration for patients using adalimumab, enhancing its market drive.

Report Covers:

This report presents an overview of global market for Adalimumab, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Adalimumab, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Adalimumab, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Adalimumab sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Adalimumab market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Adalimumab sales, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of Adalimumab Market Report

Report Metric	Details
Report Name	Adalimumab Market
Accounted market size in 2024	US$ 148 million
Forecasted market size in 2030	US$ 192.7 million
CAGR	4.5
Base Year	2024
Forecasted years	2025 - 2030
Segment by Type	Adalimumab Adalimumab Biosimilar
Segment by Application	Adults Children
Segment by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sandoz, Boehringer Ingelheim, Mylan, Biogen, Aark Pharmaceuticals, Amgevita, Delphis Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Adalimumab in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Adalimumab manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Adalimumab sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

FAQ for this report

How fast is Adalimumab Market growing?

Ans: The Adalimumab Market witnessing a CAGR of 4.5 during the forecast period 2025-2030.

What is the Adalimumab Market size in 2030?

Ans: The Adalimumab Market size in 2030 will be US$ 192.7 million.

Who are the main players in the Adalimumab Market report?

Ans: The main players in the Adalimumab Market are Sandoz, Boehringer Ingelheim, Mylan, Biogen, Aark Pharmaceuticals, Amgevita, Delphis Pharma

What are the Application segmentation covered in the Adalimumab Market report?

Ans: The Applications covered in the Adalimumab Market report are Adults, Children

What are the Type segmentation covered in the Adalimumab Market report?

Ans: The Types covered in the Adalimumab Market report are Adalimumab, Adalimumab Biosimilar

1 Study Coverage

1.1 Adalimumab Product Introduction

1.2 Market by Type

1.2.1 Global Adalimumab Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 Adalimumab

1.2.3 Adalimumab Biosimilar

1.3 Market by Application

1.3.1 Global Adalimumab Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Adults

1.3.3 Children

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Adalimumab Sales Estimates and Forecasts 2019-2030

2.2 Global Adalimumab Revenue by Region

2.2.1 Global Adalimumab Revenue by Region: 2019 VS 2023 VS 2030

2.2.2 Global Adalimumab Revenue by Region (2019-2024)

2.2.3 Global Adalimumab Revenue by Region (2025-2030)

2.2.4 Global Adalimumab Revenue Market Share by Region (2019-2030)

2.3 Global Adalimumab Sales Estimates and Forecasts 2019-2030

2.4 Global Adalimumab Sales by Region

2.4.1 Global Adalimumab Sales by Region: 2019 VS 2023 VS 2030

2.4.2 Global Adalimumab Sales by Region (2019-2024)

2.4.3 Global Adalimumab Sales by Region (2025-2030)

2.4.4 Global Adalimumab Sales Market Share by Region (2019-2030)

2.5 US & Canada

2.6 Europe

2.7 China

2.8 Asia (excluding China)

2.9 Middle East, Africa and Latin America

3 Competition by Manufactures

3.1 Global Adalimumab Sales by Manufacturers

3.1.1 Global Adalimumab Sales by Manufacturers (2019-2024)

3.1.2 Global Adalimumab Sales Market Share by Manufacturers (2019-2024)

3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Adalimumab in 2023

3.2 Global Adalimumab Revenue by Manufacturers

3.2.1 Global Adalimumab Revenue by Manufacturers (2019-2024)

3.2.2 Global Adalimumab Revenue Market Share by Manufacturers (2019-2024)

3.2.3 Global Top 10 and Top 5 Companies by Adalimumab Revenue in 2023

3.3 Global Key Players of Adalimumab, Industry Ranking, 2022 VS 2023 VS 2024

3.4 Global Adalimumab Sales Price by Manufacturers

3.5 Analysis of Competitive Landscape

3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

3.5.2 Global Adalimumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.6 Global Key Manufacturers of Adalimumab, Manufacturing Base Distribution and Headquarters

3.7 Global Key Manufacturers of Adalimumab, Product Offered and Application

3.8 Global Key Manufacturers of Adalimumab, Date of Enter into This Industry

3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

4.1 Global Adalimumab Sales by Type

4.1.1 Global Adalimumab Historical Sales by Type (2019-2024)

4.1.2 Global Adalimumab Forecasted Sales by Type (2025-2030)

4.1.3 Global Adalimumab Sales Market Share by Type (2019-2030)

4.2 Global Adalimumab Revenue by Type

4.2.1 Global Adalimumab Historical Revenue by Type (2019-2024)

4.2.2 Global Adalimumab Forecasted Revenue by Type (2025-2030)

4.2.3 Global Adalimumab Revenue Market Share by Type (2019-2030)

4.3 Global Adalimumab Price by Type

4.3.1 Global Adalimumab Price by Type (2019-2024)

4.3.2 Global Adalimumab Price Forecast by Type (2025-2030)

5 Market Size by Application

5.1 Global Adalimumab Sales by Application

5.1.1 Global Adalimumab Historical Sales by Application (2019-2024)

5.1.2 Global Adalimumab Forecasted Sales by Application (2025-2030)

5.1.3 Global Adalimumab Sales Market Share by Application (2019-2030)

5.2 Global Adalimumab Revenue by Application

5.2.1 Global Adalimumab Historical Revenue by Application (2019-2024)

5.2.2 Global Adalimumab Forecasted Revenue by Application (2025-2030)

5.2.3 Global Adalimumab Revenue Market Share by Application (2019-2030)

5.3 Global Adalimumab Price by Application

5.3.1 Global Adalimumab Price by Application (2019-2024)

5.3.2 Global Adalimumab Price Forecast by Application (2025-2030)

6 US & Canada

6.1 US & Canada Adalimumab Market Size by Type

6.1.1 US & Canada Adalimumab Sales by Type (2019-2030)

6.1.2 US & Canada Adalimumab Revenue by Type (2019-2030)

6.2 US & Canada Adalimumab Market Size by Application

6.2.1 US & Canada Adalimumab Sales by Application (2019-2030)

6.2.2 US & Canada Adalimumab Revenue by Application (2019-2030)

6.3 US & Canada Adalimumab Market Size by Country

6.3.1 US & Canada Adalimumab Revenue by Country: 2019 VS 2023 VS 2030

6.3.2 US & Canada Adalimumab Sales by Country (2019-2030)

6.3.3 US & Canada Adalimumab Revenue by Country (2019-2030)

6.3.4 US

6.3.5 Canada

7 Europe

7.1 Europe Adalimumab Market Size by Type

7.1.1 Europe Adalimumab Sales by Type (2019-2030)

7.1.2 Europe Adalimumab Revenue by Type (2019-2030)

7.2 Europe Adalimumab Market Size by Application

7.2.1 Europe Adalimumab Sales by Application (2019-2030)

7.2.2 Europe Adalimumab Revenue by Application (2019-2030)

7.3 Europe Adalimumab Market Size by Country

7.3.1 Europe Adalimumab Revenue by Country: 2019 VS 2023 VS 2030

7.3.2 Europe Adalimumab Sales by Country (2019-2030)

7.3.3 Europe Adalimumab Revenue by Country (2019-2030)

7.3.4 Germany

7.3.5 France

7.3.6 U.K.

7.3.7 Italy

7.3.8 Russia

8 China

8.1 China Adalimumab Market Size

8.1.1 China Adalimumab Sales (2019-2030)

8.1.2 China Adalimumab Revenue (2019-2030)

8.2 China Adalimumab Market Size by Application

8.2.1 China Adalimumab Sales by Application (2019-2030)

8.2.2 China Adalimumab Revenue by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Adalimumab Market Size by Type

9.1.1 Asia Adalimumab Sales by Type (2019-2030)

9.1.2 Asia Adalimumab Revenue by Type (2019-2030)

9.2 Asia Adalimumab Market Size by Application

9.2.1 Asia Adalimumab Sales by Application (2019-2030)

9.2.2 Asia Adalimumab Revenue by Application (2019-2030)

9.3 Asia Adalimumab Sales by Region

9.3.1 Asia Adalimumab Revenue by Region: 2019 VS 2023 VS 2030

9.3.2 Asia Adalimumab Revenue by Region (2019-2030)

9.3.3 Asia Adalimumab Sales by Region (2019-2030)

9.3.4 Japan

9.3.5 South Korea

9.3.6 China Taiwan

9.3.7 Southeast Asia

9.3.8 India

10 Middle East, Africa and Latin America

10.1 Middle East, Africa and Latin America Adalimumab Market Size by Type

10.1.1 Middle East, Africa and Latin America Adalimumab Sales by Type (2019-2030)

10.1.2 Middle East, Africa and Latin America Adalimumab Revenue by Type (2019-2030)

10.2 Middle East, Africa and Latin America Adalimumab Market Size by Application

10.2.1 Middle East, Africa and Latin America Adalimumab Sales by Application (2019-2030)

10.2.2 Middle East, Africa and Latin America Adalimumab Revenue by Application (2019-2030)

10.3 Middle East, Africa and Latin America Adalimumab Sales by Country

10.3.1 Middle East, Africa and Latin America Adalimumab Revenue by Country: 2019 VS 2023 VS 2030

10.3.2 Middle East, Africa and Latin America Adalimumab Revenue by Country (2019-2030)

10.3.3 Middle East, Africa and Latin America Adalimumab Sales by Country (2019-2030)

10.3.4 Brazil

10.3.5 Mexico

10.3.6 Turkey

10.3.7 Israel

10.3.8 GCC Countries

11 Company Profiles

11.1 AbbVie

11.1.1 AbbVie Company Information

11.1.2 AbbVie Overview

11.1.3 AbbVie Adalimumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.1.4 AbbVie Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

11.1.5 AbbVie Recent Developments

11.2 Amgen

11.2.1 Amgen Company Information

11.2.2 Amgen Overview

11.2.3 Amgen Adalimumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.2.4 Amgen Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

11.2.5 Amgen Recent Developments

11.3 Sandoz

11.3.1 Sandoz Company Information

11.3.2 Sandoz Overview

11.3.3 Sandoz Adalimumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.3.4 Sandoz Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

11.3.5 Sandoz Recent Developments

11.4 Boehringer Ingelheim

11.4.1 Boehringer Ingelheim Company Information

11.4.2 Boehringer Ingelheim Overview

11.4.3 Boehringer Ingelheim Adalimumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.4.4 Boehringer Ingelheim Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

11.4.5 Boehringer Ingelheim Recent Developments

11.5 Mylan

11.5.1 Mylan Company Information

11.5.2 Mylan Overview

11.5.3 Mylan Adalimumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.5.4 Mylan Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

11.5.5 Mylan Recent Developments

11.6 Biogen

11.6.1 Biogen Company Information

11.6.2 Biogen Overview

11.6.3 Biogen Adalimumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.6.4 Biogen Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

11.6.5 Biogen Recent Developments

11.7 Aark Pharmaceuticals

11.7.1 Aark Pharmaceuticals Company Information

11.7.2 Aark Pharmaceuticals Overview

11.7.3 Aark Pharmaceuticals Adalimumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.7.4 Aark Pharmaceuticals Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

11.7.5 Aark Pharmaceuticals Recent Developments

11.8 Amgevita

11.8.1 Amgevita Company Information

11.8.2 Amgevita Overview

11.8.3 Amgevita Adalimumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.8.4 Amgevita Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

11.8.5 Amgevita Recent Developments

11.9 Delphis Pharma

11.9.1 Delphis Pharma Company Information

11.9.2 Delphis Pharma Overview

11.9.3 Delphis Pharma Adalimumab Sales, Price, Revenue and Gross Margin (2019-2024)

11.9.4 Delphis Pharma Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

11.9.5 Delphis Pharma Recent Developments

12 Industry Chain and Sales Channels Analysis

12.1 Adalimumab Industry Chain Analysis

12.2 Adalimumab Key Raw Materials

12.2.1 Key Raw Materials

12.2.2 Raw Materials Key Suppliers

12.3 Adalimumab Production Mode & Process

12.4 Adalimumab Sales and Marketing

12.4.1 Adalimumab Sales Channels

12.4.2 Adalimumab Distributors

12.5 Adalimumab Customers

13 Market Dynamics

13.1 Adalimumab Industry Trends

13.2 Adalimumab Market Drivers

13.3 Adalimumab Market Challenges

13.4 Adalimumab Market Restraints

14 Key Findings in The Global Adalimumab Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author Details

15.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Adalimumab Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Table 2. Major Manufacturers of Adalimumab

Table 3. Major Manufacturers of Adalimumab Biosimilar

Table 4. Global Adalimumab Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Table 5. Global Adalimumab Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 6. Global Adalimumab Revenue by Region (2019-2024) & (US$ Million)

Table 7. Global Adalimumab Revenue by Region (2025-2030) & (US$ Million)

Table 8. Global Adalimumab Revenue Market Share by Region (2019-2024)

Table 9. Global Adalimumab Revenue Market Share by Region (2025-2030)

Table 10. Global Adalimumab Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 11. Global Adalimumab Sales by Region (2019-2024) & (K Units)

Table 12. Global Adalimumab Sales by Region (2025-2030) & (K Units)

Table 13. Global Adalimumab Sales Market Share by Region (2019-2024)

Table 14. Global Adalimumab Sales Market Share by Region (2025-2030)

Table 15. Global Adalimumab Sales by Manufacturers (2019-2024) & (K Units)

Table 16. Global Adalimumab Sales Share by Manufacturers (2019-2024)

Table 17. Global Adalimumab Revenue by Manufacturers (2019-2024) & (US$ Million)

Table 18. Global Adalimumab Revenue Share by Manufacturers (2019-2024)

Table 19. Global Key Players of Adalimumab, Industry Ranking, 2022 VS 2023 VS 2024

Table 20. Adalimumab Price by Manufacturers 2019-2024 (USD/Unit)

Table 21. Global Adalimumab Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 22. Global Adalimumab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab as of 2023)

Table 23. Global Key Manufacturers of Adalimumab, Manufacturing Base Distribution and Headquarters

Table 24. Global Key Manufacturers of Adalimumab, Product Offered and Application

Table 25. Global Key Manufacturers of Adalimumab, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global Adalimumab Sales by Type (2019-2024) & (K Units)

Table 28. Global Adalimumab Sales by Type (2025-2030) & (K Units)

Table 29. Global Adalimumab Sales Share by Type (2019-2024)

Table 30. Global Adalimumab Sales Share by Type (2025-2030)

Table 31. Global Adalimumab Revenue by Type (2019-2024) & (US$ Million)

Table 32. Global Adalimumab Revenue by Type (2025-2030) & (US$ Million)

Table 33. Global Adalimumab Revenue Share by Type (2019-2024)

Table 34. Global Adalimumab Revenue Share by Type (2025-2030)

Table 35. Adalimumab Price by Type (2019-2024) & (USD/Unit)

Table 36. Global Adalimumab Price Forecast by Type (2025-2030) & (USD/Unit)

Table 37. Global Adalimumab Sales by Application (2019-2024) & (K Units)

Table 38. Global Adalimumab Sales by Application (2025-2030) & (K Units)

Table 39. Global Adalimumab Sales Share by Application (2019-2024)

Table 40. Global Adalimumab Sales Share by Application (2025-2030)

Table 41. Global Adalimumab Revenue by Application (2019-2024) & (US$ Million)

Table 42. Global Adalimumab Revenue by Application (2025-2030) & (US$ Million)

Table 43. Global Adalimumab Revenue Share by Application (2019-2024)

Table 44. Global Adalimumab Revenue Share by Application (2025-2030)

Table 45. Adalimumab Price by Application (2019-2024) & (USD/Unit)

Table 46. Global Adalimumab Price Forecast by Application (2025-2030) & (USD/Unit)

Table 47. US & Canada Adalimumab Sales by Type (2019-2024) & (K Units)

Table 48. US & Canada Adalimumab Sales by Type (2025-2030) & (K Units)

Table 49. US & Canada Adalimumab Revenue by Type (2019-2024) & (US$ Million)

Table 50. US & Canada Adalimumab Revenue by Type (2025-2030) & (US$ Million)

Table 51. US & Canada Adalimumab Sales by Application (2019-2024) & (K Units)

Table 52. US & Canada Adalimumab Sales by Application (2025-2030) & (K Units)

Table 53. US & Canada Adalimumab Revenue by Application (2019-2024) & (US$ Million)

Table 54. US & Canada Adalimumab Revenue by Application (2025-2030) & (US$ Million)

Table 55. US & Canada Adalimumab Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 56. US & Canada Adalimumab Revenue by Country (2019-2024) & (US$ Million)

Table 57. US & Canada Adalimumab Revenue by Country (2025-2030) & (US$ Million)

Table 58. US & Canada Adalimumab Sales by Country (2019-2024) & (K Units)

Table 59. US & Canada Adalimumab Sales by Country (2025-2030) & (K Units)

Table 60. Europe Adalimumab Sales by Type (2019-2024) & (K Units)

Table 61. Europe Adalimumab Sales by Type (2025-2030) & (K Units)

Table 62. Europe Adalimumab Revenue by Type (2019-2024) & (US$ Million)

Table 63. Europe Adalimumab Revenue by Type (2025-2030) & (US$ Million)

Table 64. Europe Adalimumab Sales by Application (2019-2024) & (K Units)

Table 65. Europe Adalimumab Sales by Application (2025-2030) & (K Units)

Table 66. Europe Adalimumab Revenue by Application (2019-2024) & (US$ Million)

Table 67. Europe Adalimumab Revenue by Application (2025-2030) & (US$ Million)

Table 68. Europe Adalimumab Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 69. Europe Adalimumab Revenue by Country (2019-2024) & (US$ Million)

Table 70. Europe Adalimumab Revenue by Country (2025-2030) & (US$ Million)

Table 71. Europe Adalimumab Sales by Country (2019-2024) & (K Units)

Table 72. Europe Adalimumab Sales by Country (2025-2030) & (K Units)

Table 73. China Adalimumab Sales by Type (2019-2024) & (K Units)

Table 74. China Adalimumab Sales by Type (2025-2030) & (K Units)

Table 75. China Adalimumab Revenue by Type (2019-2024) & (US$ Million)

Table 76. China Adalimumab Revenue by Type (2025-2030) & (US$ Million)

Table 77. China Adalimumab Sales by Application (2019-2024) & (K Units)

Table 78. China Adalimumab Sales by Application (2025-2030) & (K Units)

Table 79. China Adalimumab Revenue by Application (2019-2024) & (US$ Million)

Table 80. China Adalimumab Revenue by Application (2025-2030) & (US$ Million)

Table 81. Asia Adalimumab Sales by Type (2019-2024) & (K Units)

Table 82. Asia Adalimumab Sales by Type (2025-2030) & (K Units)

Table 83. Asia Adalimumab Revenue by Type (2019-2024) & (US$ Million)

Table 84. Asia Adalimumab Revenue by Type (2025-2030) & (US$ Million)

Table 85. Asia Adalimumab Sales by Application (2019-2024) & (K Units)

Table 86. Asia Adalimumab Sales by Application (2025-2030) & (K Units)

Table 87. Asia Adalimumab Revenue by Application (2019-2024) & (US$ Million)

Table 88. Asia Adalimumab Revenue by Application (2025-2030) & (US$ Million)

Table 89. Asia Adalimumab Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 90. Asia Adalimumab Revenue by Region (2019-2024) & (US$ Million)

Table 91. Asia Adalimumab Revenue by Region (2025-2030) & (US$ Million)

Table 92. Asia Adalimumab Sales by Region (2019-2024) & (K Units)

Table 93. Asia Adalimumab Sales by Region (2025-2030) & (K Units)

Table 94. Middle East, Africa and Latin America Adalimumab Sales by Type (2019-2024) & (K Units)

Table 95. Middle East, Africa and Latin America Adalimumab Sales by Type (2025-2030) & (K Units)

Table 96. Middle East, Africa and Latin America Adalimumab Revenue by Type (2019-2024) & (US$ Million)

Table 97. Middle East, Africa and Latin America Adalimumab Revenue by Type (2025-2030) & (US$ Million)

Table 98. Middle East, Africa and Latin America Adalimumab Sales by Application (2019-2024) & (K Units)

Table 99. Middle East, Africa and Latin America Adalimumab Sales by Application (2025-2030) & (K Units)

Table 100. Middle East, Africa and Latin America Adalimumab Revenue by Application (2019-2024) & (US$ Million)

Table 101. Middle East, Africa and Latin America Adalimumab Revenue by Application (2025-2030) & (US$ Million)

Table 102. Middle East, Africa and Latin America Adalimumab Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 103. Middle East, Africa and Latin America Adalimumab Revenue by Country (2019-2024) & (US$ Million)

Table 104. Middle East, Africa and Latin America Adalimumab Revenue by Country (2025-2030) & (US$ Million)

Table 105. Middle East, Africa and Latin America Adalimumab Sales by Country (2019-2024) & (K Units)

Table 106. Middle East, Africa and Latin America Adalimumab Sales by Country (2025-2030) & (K Units)

Table 107. AbbVie Company Information

Table 108. AbbVie Description and Major Businesses

Table 109. AbbVie Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 110. AbbVie Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 111. AbbVie Recent Developments

Table 112. Amgen Company Information

Table 113. Amgen Description and Major Businesses

Table 114. Amgen Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 115. Amgen Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 116. Amgen Recent Developments

Table 117. Sandoz Company Information

Table 118. Sandoz Description and Major Businesses

Table 119. Sandoz Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 120. Sandoz Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 121. Sandoz Recent Developments

Table 122. Boehringer Ingelheim Company Information

Table 123. Boehringer Ingelheim Description and Major Businesses

Table 124. Boehringer Ingelheim Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 125. Boehringer Ingelheim Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 126. Boehringer Ingelheim Recent Developments

Table 127. Mylan Company Information

Table 128. Mylan Description and Major Businesses

Table 129. Mylan Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 130. Mylan Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 131. Mylan Recent Developments

Table 132. Biogen Company Information

Table 133. Biogen Description and Major Businesses

Table 134. Biogen Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 135. Biogen Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 136. Biogen Recent Developments

Table 137. Aark Pharmaceuticals Company Information

Table 138. Aark Pharmaceuticals Description and Major Businesses

Table 139. Aark Pharmaceuticals Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 140. Aark Pharmaceuticals Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 141. Aark Pharmaceuticals Recent Developments

Table 142. Amgevita Company Information

Table 143. Amgevita Description and Major Businesses

Table 144. Amgevita Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 145. Amgevita Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 146. Amgevita Recent Developments

Table 147. Delphis Pharma Company Information

Table 148. Delphis Pharma Description and Major Businesses

Table 149. Delphis Pharma Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 150. Delphis Pharma Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications

Table 151. Delphis Pharma Recent Developments

Table 152. Key Raw Materials Lists

Table 153. Raw Materials Key Suppliers Lists

Table 154. Adalimumab Distributors List

Table 155. Adalimumab Customers List

Table 156. Adalimumab Market Trends

Table 157. Adalimumab Market Drivers

Table 158. Adalimumab Market Challenges

Table 159. Adalimumab Market Restraints

Table 160. Research Programs/Design for This Report

Table 161. Key Data Information from Secondary Sources

Table 162. Key Data Information from Primary Sources

List of Figures

Figure 1. Adalimumab Product Picture

Figure 2. Global Adalimumab Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Adalimumab Market Share by Type in 2023 & 2030

Figure 4. Adalimumab Product Picture

Figure 5. Adalimumab Biosimilar Product Picture

Figure 6. Global Adalimumab Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 7. Global Adalimumab Market Share by Application in 2023 & 2030

Figure 8. Adults

Figure 9. Children

Figure 10. Adalimumab Report Years Considered

Figure 11. Global Adalimumab Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 12. Global Adalimumab Revenue 2019-2030 (US$ Million)

Figure 13. Global Adalimumab Revenue Market Share by Region in Percentage: 2023 Versus 2030

Figure 14. Global Adalimumab Revenue Market Share by Region (2019-2030)

Figure 15. Global Adalimumab Sales 2019-2030 ((K Units)

Figure 16. Global Adalimumab Sales Market Share by Region (2019-2030)

Figure 17. US & Canada Adalimumab Sales YoY (2019-2030) & (K Units)

Figure 18. US & Canada Adalimumab Revenue YoY (2019-2030) & (US$ Million)

Figure 19. Europe Adalimumab Sales YoY (2019-2030) & (K Units)

Figure 20. Europe Adalimumab Revenue YoY (2019-2030) & (US$ Million)

Figure 21. China Adalimumab Sales YoY (2019-2030) & (K Units)

Figure 22. China Adalimumab Revenue YoY (2019-2030) & (US$ Million)

Figure 23. Asia (excluding China) Adalimumab Sales YoY (2019-2030) & (K Units)

Figure 24. Asia (excluding China) Adalimumab Revenue YoY (2019-2030) & (US$ Million)

Figure 25. Middle East, Africa and Latin America Adalimumab Sales YoY (2019-2030) & (K Units)

Figure 26. Middle East, Africa and Latin America Adalimumab Revenue YoY (2019-2030) & (US$ Million)

Figure 27. The Adalimumab Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023

Figure 28. The Top 5 and 10 Largest Manufacturers of Adalimumab in the World: Market Share by Adalimumab Revenue in 2023

Figure 29. Global Adalimumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 30. Global Adalimumab Sales Market Share by Type (2019-2030)

Figure 31. Global Adalimumab Revenue Market Share by Type (2019-2030)

Figure 32. Global Adalimumab Sales Market Share by Application (2019-2030)

Figure 33. Global Adalimumab Revenue Market Share by Application (2019-2030)

Figure 34. US & Canada Adalimumab Sales Market Share by Type (2019-2030)

Figure 35. US & Canada Adalimumab Revenue Market Share by Type (2019-2030)

Figure 36. US & Canada Adalimumab Sales Market Share by Application (2019-2030)

Figure 37. US & Canada Adalimumab Revenue Market Share by Application (2019-2030)

Figure 38. US & Canada Adalimumab Revenue Share by Country (2019-2030)

Figure 39. US & Canada Adalimumab Sales Share by Country (2019-2030)

Figure 40. U.S. Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 41. Canada Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 42. Europe Adalimumab Sales Market Share by Type (2019-2030)

Figure 43. Europe Adalimumab Revenue Market Share by Type (2019-2030)

Figure 44. Europe Adalimumab Sales Market Share by Application (2019-2030)

Figure 45. Europe Adalimumab Revenue Market Share by Application (2019-2030)

Figure 46. Europe Adalimumab Revenue Share by Country (2019-2030)

Figure 47. Europe Adalimumab Sales Share by Country (2019-2030)

Figure 48. Germany Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 49. France Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 50. U.K. Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 51. Italy Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 52. Russia Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 53. China Adalimumab Sales Market Share by Type (2019-2030)

Figure 54. China Adalimumab Revenue Market Share by Type (2019-2030)

Figure 55. China Adalimumab Sales Market Share by Application (2019-2030)

Figure 56. China Adalimumab Revenue Market Share by Application (2019-2030)

Figure 57. Asia Adalimumab Sales Market Share by Type (2019-2030)

Figure 58. Asia Adalimumab Revenue Market Share by Type (2019-2030)

Figure 59. Asia Adalimumab Sales Market Share by Application (2019-2030)

Figure 60. Asia Adalimumab Revenue Market Share by Application (2019-2030)

Figure 61. Asia Adalimumab Revenue Share by Region (2019-2030)

Figure 62. Asia Adalimumab Sales Share by Region (2019-2030)

Figure 63. Japan Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 64. South Korea Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 65. China Taiwan Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 66. Southeast Asia Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 67. India Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 68. Middle East, Africa and Latin America Adalimumab Sales Market Share by Type (2019-2030)

Figure 69. Middle East, Africa and Latin America Adalimumab Revenue Market Share by Type (2019-2030)

Figure 70. Middle East, Africa and Latin America Adalimumab Sales Market Share by Application (2019-2030)

Figure 71. Middle East, Africa and Latin America Adalimumab Revenue Market Share by Application (2019-2030)

Figure 72. Middle East, Africa and Latin America Adalimumab Revenue Share by Country (2019-2030)

Figure 73. Middle East, Africa and Latin America Adalimumab Sales Share by Country (2019-2030)

Figure 74. Brazil Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 75. Mexico Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 76. Turkey Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 77. Israel Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 78. GCC Countries Adalimumab Revenue (2019-2030) & (US$ Million)

Figure 79. Adalimumab Value Chain

Figure 80. Adalimumab Production Process

Figure 81. Channels of Distribution

Figure 82. Distributors Profiles

Figure 83. Bottom-up and Top-down Approaches for This Report

Figure 84. Data Triangulation

Figure 85. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions